organization · Reporting owner

Column Group Management LP

Disclosed activity across 1 company

Tapewire entity: 92150
SEC CIK: 0001645340

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NGM BIOPHARMACEUTICALS INCNGM · Entity 11997	10% owner	April 05, 2024	April 08, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Jointly reported with COLUMN GROUP L P, Svennilson Peter, Kutzkey Tim, Ponoi Capital II, LP, Ponoi II Management, LLC, PONOI CAPITAL, LP, Ponoi Management, LLC, COLUMN GROUP II, LP, Column Group II GP, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2024-04-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,000	Reported balance After 2024-04-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-04-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F15: The securities were owned solely by Tim Kutzkey.

F16: The securities were directly held by Peter Svennilson.

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 19, 2022 Filed May 23, 2022 16:12 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	682	$13.25	$9,039.71	Disclosure SEC source: 0000899243-22-019208 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 48,359 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 19, 2022 Filed May 23, 2022 16:12 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	19,984	$13.25	$264,881.92	Disclosure SEC source: 0000899243-22-019208 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,417,028 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 18, 2022 Filed May 19, 2022 16:35 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,067	$13.20	$27,292.46	Disclosure SEC source: 0000899243-22-018848 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 47,677 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.98 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 18, 2022 Filed May 19, 2022 16:35 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	60,583	$13.20	$799,931.87	Disclosure SEC source: 0000899243-22-018848 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,397,044 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.98 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 17, 2022 Filed May 19, 2022 16:35 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,939	$13.42	$39,432.86	Disclosure SEC source: 0000899243-22-018848 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 45,610 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.90 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 17, 2022 Filed May 19, 2022 16:35 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	86,110	$13.42	$1,155,346.48	Disclosure SEC source: 0000899243-22-018848 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,336,461 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.90 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 16, 2022 Filed May 17, 2022 16:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	1,094	$12.90	$14,114.24	Disclosure SEC source: 0000899243-22-018399 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 42,671 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 16, 2022 Filed May 17, 2022 16:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	32,072	$12.90	$413,776.91	Disclosure SEC source: 0000899243-22-018399 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,250,351 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 13, 2022 Filed May 17, 2022 16:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	4,269	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-018399 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 41,577 F1 · price: Represents a purchase of common stock pursuant to a block trade at a price of $11.29 per share. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 13, 2022 Filed May 17, 2022 16:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	125,096	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-018399 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,218,279 F1 · price: Represents a purchase of common stock pursuant to a block trade at a price of $11.29 per share. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 12, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	17	$11.81	$200.70	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 8 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 37,308 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.74 to $11.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 12, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	485	$11.81	$5,725.76	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,093,183 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.74 to $11.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 12, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,728	$11.62	$31,702.36	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 37,291 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.73 to $11.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 12, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	79,945	$11.62	$929,048.84	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,092,698 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.73 to $11.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 11, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	88	$11.85	$1,042.56	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,563 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.76 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 11, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,564	$11.85	$30,376.48	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,012,753 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.76 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 11, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,657	$11.23	$29,826.95	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,475 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.745 to $11.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 11, 2022 Filed May 13, 2022 17:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	77,866	$11.23	$874,108.14	Disclosure SEC source: 0000899243-22-018030 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,010,189 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.745 to $11.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 10, 2022 Filed May 11, 2022 18:03 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	1,032	$11.36	$11,727.24	Disclosure SEC source: 0000899243-22-017672 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 31,818 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $10.91 to $11.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 10, 2022 Filed May 11, 2022 18:03 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	30,233	$11.36	$343,555.72	Disclosure SEC source: 0000899243-22-017672 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 932,323 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $10.91 to $11.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 09, 2022 Filed May 11, 2022 18:03 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,745	$10.79	$29,626.51	Disclosure SEC source: 0000899243-22-017672 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 30,786 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $10.62 to $11.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
May 09, 2022 Filed May 11, 2022 18:03 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	80,430	$10.79	$868,072.95	Disclosure SEC source: 0000899243-22-017672 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 902,090 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $10.62 to $11.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 25, 2022 Filed Jan 26, 2022 19:12 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	19,791	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-003318 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 28,041 F4 · price: Represents a purchase of common stock pursuant to a block trade at a price of $14.30 per share. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 25, 2022 Filed Jan 26, 2022 19:12 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	579,910	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-003318 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 821,660 F4 · price: Represents a purchase of common stock pursuant to a block trade at a price of $14.30 per share. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 24, 2022 Filed Jan 26, 2022 19:12 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	8,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-003318 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,250 F1 · price: Represents a purchase of common stock pursuant to a block trade at a price of $14.64 per share. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 24, 2022 Filed Jan 26, 2022 19:12 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	241,750	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-003318 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 241,750 F1 · price: Represents a purchase of common stock pursuant to a block trade at a price of $14.64 per share. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:31 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	27,595	$17.67	$487,603.65	Disclosure SEC source: 0001209191-20-049487 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827,025 F4 · shares: Consists of 12,960 shares of Common Stock held directly by TCG III LP and 14,635 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:31 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	36,494	$17.64	$643,754.16	Disclosure SEC source: 0001209191-20-049487 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,430 F1 · shares: Consists of 17,139 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 19,355 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 28, 2020 Filed Aug 31, 2020 17:00 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	26,135	$17.89	$467,555.15	Disclosure SEC source: 0001209191-20-048798 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,762,936 F4 · shares: Consists of 12,274 shares of Common Stock held directly by TCG III LP and 13,861 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 27, 2020 Filed Aug 31, 2020 17:00 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	36,359	$17.79	$646,826.61	Disclosure SEC source: 0001209191-20-048798 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,736,801 F1 · shares: Consists of 17,075 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 19,284 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 25, 2020 Filed Aug 25, 2020 18:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	100	$18.00	$1,800.00	Disclosure SEC source: 0001209191-20-048294 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,442 F5 · shares: Consists of 47 shares of Common Stock held directly by TCG III LP and 53 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 24, 2020 Filed Aug 25, 2020 18:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	11,024	$17.96	$197,991.04	Disclosure SEC source: 0001209191-20-048294 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,342 F4 · shares: Consists of 5,177 shares of Common Stock held directly by TCG III LP and 5,847 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 21, 2020 Filed Aug 25, 2020 18:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	7,321	$17.97	$131,558.37	Disclosure SEC source: 0001209191-20-048294 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689,318 F1 · shares: Consists of 3,438 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 3,883 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 17, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	6,425	$17.89	$114,943.25	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681,997 F5 · shares: Consists of 3,017 shares of Common Stock held directly by TCG III LP and 3,408 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 14, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	37,993	$17.49	$664,497.57	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675,572 F4 · shares: Consists of 17,843 shares of Common Stock held directly by TCG III LP and 20,150 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 13, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	19,895	$17.89	$355,921.55	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637,579 F1 · shares: Consists of 9,343 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 10,552 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 30, 2020 Filed Aug 3, 2020 17:54 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	732	$17.99	$13,168.68	Disclosure SEC source: 0001209191-20-044543 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617,684 F1 · shares: Consists of 344 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 388 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 30, 2020 19:23 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	4,105	$17.99	$73,848.95	Disclosure SEC source: 0001209191-20-044067 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,952 F1 · shares: Consists of 1,928 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 2,177 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 27, 2020 Filed Jul 28, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	3,834	$17.99	$68,973.66	Disclosure SEC source: 0001209191-20-043875 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,612,847 F4 · shares: Consists of 1,801 shares of Common Stock held directly by TCG III LP and 2,033 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 24, 2020 Filed Jul 28, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	68,749	$17.93	$1,232,669.57	Disclosure SEC source: 0001209191-20-043875 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,013 F1 · shares: Consists of 32,287 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 36,462 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 22, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	193	$18.00	$3,474.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,264 F3 · shares: Consists of 91 shares of Common Stock held directly by TCG III LP and 102 shares of Common Stock held directly by TCG III-A LP. F4 · balance_after: Consists of 723,362 shares of Common Stock held directly by TCG III LP and 816,902 shares of Common Stock held directly by TCG III-A LP. F5 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F6 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 21, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Exercise / conversionStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $13.35	$0.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · derivative · entry 9 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2020-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · security: Issued pursuant to the Issuer's Amended and Restated 2018 Equity Incentive Plan. F18 · derivative.expiration_date: The option expires 90 days from May 20, 2020, the date Mr. Svennilson's service as a director of the Issuer ceased. F1 · ownership.direct: The securities are directly held by Peter Svennilson, a former director of the Issuer who is a managing partner at The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP"), Ponoi Capital II, LP ("Ponoi II LP"), The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP," and, together with TCG II LP, Ponoi LP, Ponoi II LP and TCG III LP, the "Funds"), among other entities. Under the partnership agreements of the Funds and his agreement with The Column Group Management, LP ("TCGM LP"), Mr. Svennilson is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. F2 · ownership.direct: The securities are directly held by Peter Svennilson and certain of the securities are indirectly held by other reporting persons. See footnote 1 and related text. Mr. Svennilson disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Exercise / conversionCommon Stock	24,000	$13.35	$320,400.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The securities are directly held by Peter Svennilson, a former director of the Issuer who is a managing partner at The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP"), Ponoi Capital II, LP ("Ponoi II LP"), The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP," and, together with TCG II LP, Ponoi LP, Ponoi II LP and TCG III LP, the "Funds"), among other entities. Under the partnership agreements of the Funds and his agreement with The Column Group Management, LP ("TCGM LP"), Mr. Svennilson is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. F2 · ownership.direct: The securities are directly held by Peter Svennilson and certain of the securities are indirectly held by other reporting persons. See footnote 1 and related text. Mr. Svennilson disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 20, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	GrantStock Option (Right to Buy) · Derivative	16,806	$0.00 Strike: $20.37	$0.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · derivative · entry 8 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,806 Underlying: Common Stock · 16,806 shares Expires 2030-05-19 F16 · security: Issued pursuant to the Issuer's Amended and Restated 2018 Equity Incentive Plan. F19 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the next Issuer's annual stockholder meeting, subject to Mr. Goeddel's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. F17 · ownership.nature: The securities are directly held by David Goeddel, a director of the Issuer who is a managing partner at The Column Group which invests through the Funds, among other entities. Under the partnership agreements of the Funds and his agreement with TCGM LP, Mr. Goeddel is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Read SEC document
April 08, 2020 Filed Apr 9, 2020 17:52 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	112,602	$14.95	$1,683,399.90	Disclosure SEC source: 0001209191-20-024072 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,071 F1 · shares: Consists of 52,882 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 59,720 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 07, 2020 Filed Apr 7, 2020 19:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	123,728	$14.38	$1,779,208.64	Disclosure SEC source: 0001209191-20-023862 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,427,469 F4 · shares: Consists of 58,107 shares of Common Stock held directly by TCG III LP and 65,621 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 03, 2020 Filed Apr 7, 2020 19:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	14,587	$12.41	$181,024.67	Disclosure SEC source: 0001209191-20-023862 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,741 F1 · shares: Consists of 6,851 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 7,736 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 02, 2020 Filed Apr 2, 2020 18:07 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	14,850	$12.40	$184,140.00	Disclosure SEC source: 0001209191-20-022767 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,154 F4 · shares: Consists of 6,974 shares of Common Stock held directly by TCG III LP and 7,876 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 01, 2020 Filed Apr 2, 2020 18:07 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	118,067	$12.26	$1,447,501.42	Disclosure SEC source: 0001209191-20-022767 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,304 F1 · shares: Consists of 55,448 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 62,619 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 31, 2020 Filed Apr 2, 2020 18:07 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	118,067	$12.53	$1,479,379.51	Disclosure SEC source: 0001209191-20-022767 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156,237 F1 · shares: Consists of 55,448 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 62,619 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.